MedTrace Logo

MIND: Artemis in the Removal of Intracerebral Hemorrhage

NCT03342664 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2026-01-30

Study results available
· View outcomes & findings →

Summary

The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the treatment of intracerebral hemorrhage (ICH).

Conditions

  • Cerebral Hemorrhage
  • Brain Hemorrhage
  • Cerebral Parenchymal Hemorrhage
  • Intracerebral Hemorrhage

Interventions

DEVICE

Artemis + Medical Management

Subject will receive best MM in addition to the MIS procedure with Artemis.

OTHER

Best Medical Management Alone (MM)

Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.

Sponsors & Collaborators

  • Penumbra Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-06
Primary Completion
2024-02-20
Completion
2024-09-23
FDA Device
Yes

Countries

  • United States
  • Austria
  • Canada
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03342664 on ClinicalTrials.gov